mardi 6 juin 2017

Onco Actu du 6 juin 2017 - Spécial ASCO

5.5 ASCO

Small studies get big headlines at ASCO 2017 [HealthNewsReview]

6 things to keep in mind if you read cancer-related news in the next few days [HealthNewsReview] ASCO (général) - Industriels

Roche presents new data for TECENTRIQ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 [Roche] ASCO (général) - Académiques

At big cancer meeting, a big question: Is the U.S. ‘losing its edge’? [STAT]

5.5.10 ASCO (hémato)

Early, Durable Responses Seen with Sprycel (dasatinib) in First- and Second-Line Treatment of Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML) [BMS]

Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma [Juno]

Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia [Kite]

bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting [bluebird bio]

Long-Term IMBRUVICA® (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Disease [AbbVie]

New Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients [AbbVie]

CAR T-Cell Therapy Sends Multiple Myeloma Into Lasting Remission [ASCO]

With one BLA at the FDA, Kite hustles along impressive new leukemia data and sounds a note of caution on safety [EndPoints]

Nanjing Legend wows ASCO researchers with early data on a BCMA-targeted CAR-T contender [EndPoints]

Bluebird has a promising new update on its BCMA CAR-T for multiple myeloma, but is it still the leader? [EndPoints]

Chinese cell therapy effective in small multiple myeloma trial [Reuters]

5.5.12 ASCO (médico-éco)

SWOG clinical trials added more than 3M years of life for cancer patients, Fred Hutch researcher reports [Fred Hutch]

Thumbs up: Cancer drug R&D is exploding, get ready for the pricing debate to follow [EndPoints]

Big returns on small cancer research investment, study suggests [Reuters]

5.5.13 ASCO (divers)

Quickly reporting cancer complications may boost survival [STAT]

Web-Based System for Self-Reporting Symptoms Helps Patients Live Longer [ASCO]

How a simple tech tool can help cancer patients live longer [Washington Post] ASCO (divers-radiothérapie)

A Single Radiation Treatment Sufficiently Relieves Spinal Cord Compression Symptoms [ASCO]

One dose of radiotherapy relieves spinal cord compression in advanced cancer patients [Cancer Research UK] ASCO (divers-psy)

Remote Therapy Program Improves Quality of Life, Lowers Distress After Cancer Diagnosis [ASCO]

Psychological Intervention Relieves Distress in Patients With Advanced Cancer [ASCO]

Psychological Intervention Lowers Survivors’ Fear of Cancer Recurrence [ASCO]

Meditation reduces cancer survivors' fear of disease coming back, study finds [The Guardian]

5.5.15 ASCO (biopsies liquides)

New Technology Dives Deep Into the Cancer Genome [ASCO]

Grail passes early test in quest to find cancer in blood [Reuters]

Painless cancer detection could become routine thanks to 'liquid biopsies' [The Guardian]

5.5.16 ASCO (médecine de précision)

ASCO’s TAPUR Study Continues its Expansion of Sites, Participants, and Collaborators [ASCO]

Routine Genomic Testing is Feasible, But Only a Subset of Patients Benefit [ASCO] ASCO (médecine de précision-TRK)

A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us [Forbes]

Loxo Drug Notches Strikingly High Response Rates in Genetically Defined Tumors [The Street]

Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval [EndPoints]

New Drug Shows Durable Efficacy Across Diverse Pediatric and Adult Cancers [ASCO]

Loxo's targeted drug helps variety of advanced cancers in small study [Reuters]

Promising New Cancer Drugs Won’t Go Far Unless Everyone Gets Genetic Testing [MIT Technology Review]

5.5.18 ASCO (observation)

Steady Decrease in Severe Health Problems for Childhood Cancer Survivors [ASCO]

Childhood cancer survivors have fewer long-term side effects: study [Reuters]

Pregnancy After Breast Cancer Does Not Increase Chance of Recurrence [ASCO]

Pregnancy after breast cancer doesn't raise recurrence risk-study [Reuters]

5.5.2 ASCO (sein)

APHINITY study shows Roche’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer [Roche]

Ovarian cancer drug reduces chance certain advanced breast cancers will get worse [Cancer Research UK]

Roche Takes Another Cancer-Drug Hit [Bloomberg]

Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer [Pfizer]

Perjeta’s APHINITY for HER2+, High-Risk Breast Cancer Patients After Surgery [OBR]

MONARCH 2 Adds Semi-Sweet Results to the HR+/HER2- Breast Cancer Field [OBR]

Triumph in Breast Cancer: KuDOS to Lynparza [OBR]

AstraZeneca's Lynparza Slows Breast Cancer Caused By BRCA Mutations By 42% [Forbes]

Roche Drug Helps Keep Breast Cancer In Remission, But Tiny Benefit Stokes Hopes For Rival, Puma [Forbes]

Study Questions Value of Costly Cancer-Drug Combinations [Fox Business]

Lilly Builds Upon Body of Data for Abemaciclib with Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival in Advanced Breast Cancer [Lilly]

Adding a Second HER2 Blocker May Lower Chance of Invasive Breast Cancer for Some Women [ASCO]

Olaparib Slows Growth of BRCA-Related Metastatic Breast Cancer [ASCO]

AstraZeneca’s PARP drug Lynparza easily outscores chemo in PhIII breast cancer study [EndPoints]

Roche’s ‘success’ with its big Perjeta/Herceptin PhIII falls flat at ASCO, but it’s a boost for Puma [EndPoints]

Roche combo of breast cancer drugs shows modest benefit [Reuters]

AstraZeneca's Lynparza slows advanced breast cancer progression: study [Reuters]

5.5.3 ASCO (prostate)

Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival [Janssen]

Prostate Cancer Drug About To Confront Insurers With Sovaldi-Size Problem [Forbes]

ASCO 2017: Using targeted cancer drugs earlier in treatment – abiraterone benefits prostate cancer patients at diagnosis [Institute of Cancer Research]

LATITUDE Changes Attitude Toward Metastatic Prostate Cancer [OBR]

Abiraterone Slows Advanced Prostate Cancer, Helps Patients Live Longer [ASCO]

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival [ASCO]

Prostate cancer treatment 'could help more patients' [BBC News]

J&J’s stellar prostate cancer data signals the likelihood of a broader market approval, as Pfizer rival struggles [EndPoints]

Giving prostate cancer drug earlier extends lives of men whose disease has spread [Cancer Research UK]

Early use of J&J's Zytiga extends prostate cancer survival [Reuters]

5.5.4 ASCO (immunothérapies)

Early Research Suggests First Immunotherapy for Mesothelioma on the Horizon [ASCO]

Encouraging Disease Control Rates Observed with Nivolumab Alone or in Combination with Ipilimumab in Refractory or Relapsing Malignant Pleural Mesothelioma Patients: Results from IFCT-1501 MAPS-2 Trial [BMS]

Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy [BMS]

Opdivo (nivolumab) Data in Patients with Advanced Cervical, Vaginal and Vulvar Cancers from Phase 1/2 CheckMate -358 Presented at ASCO [BMS]

A LAG-3, Opdivo combo from Bristol-Myers offers a proof-of-concept glimpse of limited success [EndPoints]

Kite to launch mid-stage leukemia trial in fourth quarter 2017 [Reuters]

Cancer researchers weigh in on immunotherapy hype and hope [CNN] ASCO (immunothérapies-IDO)

Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer [BMS]

Incyte 'IDO' Combination Lung Cancer Results Improve Slightly at ASCO17 [The Street]

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat [EndPoints]

Next-generation cancer drugs boost immunotherapy responses [Nature]

5.5.5 ASCO (gastro-intestinal)

Global Study Sets New Risk-Based Standard to Personalize Chemotherapy for Colon Cancer After Surgery [ASCO]

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrated Promising Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer in Phase 2 CheckMate -142 Study [BMS]

Simple way to boost cancer survival rates: diet and exercise, studies say [The Guardian]

5.5.6 ASCO (peau-mélanome)

First Presentation of Efficacy Data from CheckMate -204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases [BMS]

New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients Presented at ASCO [BMS]

Combined immunotherapy could help control melanoma that has spread to the brain [Cancer Research UK]

Regeneron, Sanofi make their case for another PD-1 drug — and they’re not settling for sixth place [EndPoints]

5.5.8 ASCO (poumon)

Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer [Roche]

Research Suggests Possible New Treatment for EGFR-Positive Lung Cancer [ASCO]

Alectinib Halts Lung Cancer Growth More Than a Year Longer Than Crizotinib [ASCO]

Pfizer drug delays lung cancer growth longer than Astra's Iressa: study [Reuters]

Roche's Alecensa bests Pfizer's Xalkori in lung cancer trial [Reuters]

5.5.9 ASCO (autres organes)

Lenvima Seated Next to Nexavar in First-Line Hepatocellular Carcinoma [OBR]

Low Testosterone After Testicular Cancer Is Common, Linked to Chronic Health Problems [ASCO]